Nuvaxovid COVID-19 Vaccine recommended by CHMP as a booster for COVID caused by acute severe respiratory distress syndrome,- Novavax
Novavax, Inc. announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional marketing authorization (CMA) in the European Union (EU) as a homologous and heterologous booster for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for adults aged 18 and older.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its opinion on results from two Phase II trials, and the UK-sponsored COV-BOOST trial.
.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.